Correction: Immunotherapy for sarcomas: new frontiers and unveiled opportunities


This article has been corrected since it was first published. The overall response rate for the trial by Kelly et al (reference 97) was cited incorrectly and has now been corrected to 35% (7/20).

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.